PanOptica Doses First Patient with New Formulation of PAN-90806, a Novel, Topical Anti-VEGF Eye Drop, in Phase 1/2 Clinical Trial
BERNARDSVILLE, N.J.--(BUSINESS WIRE)--PanOptica announced that it has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806